Differential expression patterns of estrogen receptor (ER)-β splice variants between papillary thyroid cancer and nodular thyroid goiter

Medical Science Monitor

Volumn 18, Issue 9, 2012, Pages

  Dong, Wenwu ^a   Li, Jing ^a,b   Huang, Yanhong ^a,b   Zhang, Hao ^a,b   Shan, Zhongyan ^a,b   Teng, Weiping ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Endocrine Diseases   (China)

Author keywords

Estrogen receptor and beta; ; Goiter; Splice variants; Thyroid gland; Tumors

Indexed keywords

ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GENITAL SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NODULAR GOITER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID PAPILLARY CARCINOMA;

EID: 84866113270     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883344     Document Type: Article

References (27)

1. Chen AY, Jemal A, Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer, 2009; 115: 3801-7
2. Memon A, Darif M, Al-Saleh K, Suresh A: Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the Middle East. Int J Cancer, 2002; 97: 82-89
3. Ron E, Kleinerman RA, Boice JD Jr et al: A population-based case-control study of thyroid cancer. J Natl Cancer Inst, 1987; 79: 1-12
4. Preston-Martin S, Bernstein L, Pike MC et al: Thyroid cancer among young women related to prior thyroid disease and pregnancy history. Br J Cancer, 1987; 55: 191-95
5. McTiernan AM, Weiss NS, Daling JR: Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J Natl Cancer Inst, 1984; 73: 575-81
6. Persson I, Yuen J, Bergkvist L, Schairer C: Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer, 1996; 67: 327-32
7. Sioka C, Fotopoulos A: Effects of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer. Fertil Steril, 2011; 95: 1552-59
8. Yan M, Rayoo M, Takano EA; kConFab Investigators, Fox SB: Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat, 2011; 126: 395-405
9. Collins F, MacPherson S, Brown P et al: Expression of oestrogen receptors, ERalpha, ERbeta and ERbeta variants, in endometrial and cancers and evidence that prostaglandin F may play a role in regulating expression of ER alpha. BMC Cancer, 2009; 9: 330
10. Leung YK, Lam HM, Wu S et al: Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer, 2010; 17: 675-89
11. Delaunay F, Pettersson K, Tujague M, Gustafsson JA: Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol, 2000; 58: 584-90
12. Ogawa S, Inoue S, Watanabe T et al: Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res, 1998; 26: 3505-12
13. Critchley HO, Henderson TA, Kelly RW et al: Wild-type estrogen receptor (ERβ1) and the splice variant (ERβcx/b2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab, 2002; 87: 5265-73
14. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S: Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene, 2003; 22: 5011-20
15. Peng B, Lu B, Leygue E, Murphy LC: Putative functional characteristics of human estrogen receptor-β isoforms. J Mol Endocrinol, 2003; 30: 13-29
16. Zhao C, Matthews J, Tujague M et al: Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res, 2007; 67: 3955-62
17. Kawabata W, Suzuki T, Moriya T et al: Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Mod Pathol, 2003; 16: 437-44
18. Vaiman M, Olevson Y, Habler L et al: Diagnostic value of estrogen receptors in thyroid lesions. Med Sci Monit, 2010; 16(7): BR203-7
19. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immuno-histochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 1999; 17: 1474-81
20. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol, 1998; 11: 155-68
21. Liu L, Chirala M, Younes M: Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res, 2004; 24: 2919-24
22. Witte D, Chirala M, Younes A et al: Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol, 2001; 32: 940-44
23. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J et al: Increased Estrogen Receptor Bcx Expression during Mammary Carcinogenesis. Clin Cancer Res, 2005; 11: 3170-74
24. Chakravarty D, Srinivasan R, Ghosh S et al: Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer, 2007; 17: 905-13
25. Fujimura T, Takahashi S, Urano T et al: Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun, 2001; 289: 692-99
26. Wong NA, Malcomson RD, Jodrell DI et al: ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol, 2005; 207: 53-60
27. Pfeiler G, Treeck O, Wenzel G et al: Correlation of body mass index and menopausal status with the intra-tumoral estrogen system in invasive breast cancer. Gynecol Endocrinol, 2009; 25: 183-87